ATE493433T1 - Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen - Google Patents
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungenInfo
- Publication number
- ATE493433T1 ATE493433T1 AT03752132T AT03752132T ATE493433T1 AT E493433 T1 ATE493433 T1 AT E493433T1 AT 03752132 T AT03752132 T AT 03752132T AT 03752132 T AT03752132 T AT 03752132T AT E493433 T1 ATE493433 T1 AT E493433T1
- Authority
- AT
- Austria
- Prior art keywords
- immune diseases
- new composition
- treating immune
- treating
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41006202P | 2002-09-11 | 2002-09-11 | |
| PCT/US2003/028202 WO2004024068A2 (en) | 2002-09-11 | 2003-09-09 | Novel composition and methods for the treatment of immune related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493433T1 true ATE493433T1 (de) | 2011-01-15 |
Family
ID=31994051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03752132T ATE493433T1 (de) | 2002-09-11 | 2003-09-09 | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20040121370A1 (enExample) |
| EP (3) | EP1539228B1 (enExample) |
| JP (2) | JP5401001B2 (enExample) |
| AT (1) | ATE493433T1 (enExample) |
| AU (2) | AU2003270439B2 (enExample) |
| CA (1) | CA2498008C (enExample) |
| DE (1) | DE60335552D1 (enExample) |
| ES (1) | ES2357505T3 (enExample) |
| WO (1) | WO2004024068A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270439B2 (en) | 2002-09-11 | 2009-09-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| ATE515512T1 (de) * | 2005-05-12 | 2011-07-15 | Zymogenetics Inc | Zusammensetzungen und verfahren zur modulierung von immunreaktionen |
| WO2007124283A2 (en) * | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| US20100075377A1 (en) * | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
| PL3208612T3 (pl) | 2008-04-09 | 2020-03-31 | Genentech, Inc. | Kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
| AU2015202123B2 (en) * | 2008-04-09 | 2017-06-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| HRP20230078T1 (hr) | 2011-09-23 | 2023-05-12 | Mereo Biopharma 5, Inc. | Sredstva za vezivanje vegf/dll4 i njihova uporaba |
| MX384142B (es) | 2013-07-16 | 2025-03-14 | Genentech Inc | Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer. |
| TN2017000024A1 (en) | 2014-08-19 | 2018-07-04 | Merck Sharp & Dohme | Anti-tigit antibodies. |
| MX389267B (es) | 2014-12-23 | 2025-03-20 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit). |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| HUE049791T2 (hu) | 2015-02-19 | 2020-10-28 | Compugen Ltd | PVRIG elleni antitestek és alkalmazási eljárások |
| US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN108290936B (zh) | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| JP6861418B2 (ja) | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体 |
| CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
| HUE069796T2 (hu) | 2015-09-25 | 2025-04-28 | Hoffmann La Roche | Anti-TIGIT ellenanyagok és alkalmazásukra szolgáló eljárások |
| CA3000404A1 (en) | 2015-10-01 | 2017-04-06 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
| SG11201806992VA (en) | 2016-03-04 | 2018-09-27 | Jn Biosciences Llc | Antibodies to tigit |
| KR20230145510A (ko) | 2016-08-17 | 2023-10-17 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| US10759855B2 (en) | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| WO2018204363A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| AU2020314129A1 (en) | 2019-07-15 | 2022-02-24 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibodies and application thereof |
| CN115698068A (zh) | 2020-06-02 | 2023-02-03 | 艾库斯生物科学有限公司 | 抗tigit抗体 |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
| US20240067720A1 (en) | 2021-01-14 | 2024-02-29 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibody pharmaceutical composition and application thereof |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| WO2024186790A1 (en) | 2023-03-06 | 2024-09-12 | Genentech, Inc. | Prognostic and therapeutic methods for non-small cell lung cancer |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| US5169770A (en) | 1987-12-21 | 1992-12-08 | The University Of Toledo | Agrobacterium mediated transformation of germinating plant seeds |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ES2038579T3 (es) | 1989-04-28 | 1997-02-16 | Rhein Biotech Proz & Prod Gmbh | Celulas de levadura del genero schwanniomyces. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| EP0616812B1 (en) | 1993-03-24 | 1999-11-03 | Berlex Biosciences | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer |
| US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| DK1516629T3 (da) | 1996-11-27 | 2013-06-03 | Genentech Inc | Humaniseret anti-CD-11a antibodies |
| WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
| US6518033B1 (en) | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
| AU3514400A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2002539814A (ja) * | 1999-03-26 | 2002-11-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５０個のヒト分泌タンパク質 |
| US7282570B2 (en) * | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| ATE368110T1 (de) * | 1999-07-20 | 2007-08-15 | Genentech Inc | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
| US20080050809A1 (en) * | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| AU1220001A (en) | 1999-10-20 | 2001-04-30 | Zymogenetics Inc. | Novel proteins and polynucleotides encoding them |
| US20040219521A1 (en) * | 2000-01-21 | 2004-11-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2001249727A1 (en) | 2000-03-31 | 2001-10-15 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| AU2001249673A1 (en) | 2000-04-04 | 2001-10-15 | Schering Corporation | Isolated nucleic acids from micromonospora rosaria plasmid pmr2 and vectors made therefrom |
| ES2300340T3 (es) | 2000-06-06 | 2008-06-16 | Bristol-Myers Squibb Company | Acidos nucleicos y polipeptidos relacionados con b7 y sus usos para inmunomodulacion. |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US20040101876A1 (en) | 2002-05-31 | 2004-05-27 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2002366951A1 (en) | 2001-12-10 | 2003-07-09 | Nuvelo,Inc. | Novel nucleic acids and polypeptides |
| AU2003211112A1 (en) * | 2002-02-13 | 2003-09-04 | Incyte Corporation | Secreted proteins |
| CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| AU2003270439B2 (en) | 2002-09-11 | 2009-09-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| AU2003276874B2 (en) | 2002-09-11 | 2009-09-03 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| EP2343318A3 (en) | 2003-11-28 | 2013-02-27 | MedImmune Limited | Antibodies binding to a C-terminal fragment of apolipoprotein E |
| CN101035807A (zh) | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec－6相关疾病的诊断和治疗 |
| AR052774A1 (es) | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| ATE515512T1 (de) | 2005-05-12 | 2011-07-15 | Zymogenetics Inc | Zusammensetzungen und verfahren zur modulierung von immunreaktionen |
| US20100075377A1 (en) | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
| WO2007124283A2 (en) | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| CA2648925A1 (en) | 2006-04-13 | 2007-10-25 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| WO2007124383A2 (en) | 2006-04-19 | 2007-11-01 | Oregon Health & Science University | 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members |
| PL3208612T3 (pl) | 2008-04-09 | 2020-03-31 | Genentech, Inc. | Kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2802017A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| EP2812022B1 (en) | 2012-02-06 | 2019-06-26 | Providence Health & Services - Oregon | Method of monitoring cancer treatment using ox40 agonists |
| US20150322119A1 (en) | 2012-12-03 | 2015-11-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| TW201439115A (zh) | 2012-12-04 | 2014-10-16 | Oncomed Pharm Inc | 使用結合劑之免疫治療 |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| MX384142B (es) | 2013-07-16 | 2025-03-14 | Genentech Inc | Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer. |
| CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| JP6637439B2 (ja) | 2014-03-31 | 2020-01-29 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体及び使用方法 |
| CR20170014A (es) | 2014-07-16 | 2017-10-17 | Hoffmann La Roche | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer |
| CA2963974A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| HUE069796T2 (hu) | 2015-09-25 | 2025-04-28 | Hoffmann La Roche | Anti-TIGIT ellenanyagok és alkalmazásukra szolgáló eljárások |
-
2003
- 2003-09-09 AU AU2003270439A patent/AU2003270439B2/en not_active Expired
- 2003-09-09 AT AT03752132T patent/ATE493433T1/de active
- 2003-09-09 CA CA2498008A patent/CA2498008C/en not_active Expired - Lifetime
- 2003-09-09 ES ES03752132T patent/ES2357505T3/es not_active Expired - Lifetime
- 2003-09-09 EP EP03752132A patent/EP1539228B1/en not_active Expired - Lifetime
- 2003-09-09 WO PCT/US2003/028202 patent/WO2004024068A2/en not_active Ceased
- 2003-09-09 US US10/658,482 patent/US20040121370A1/en not_active Abandoned
- 2003-09-09 JP JP2004536371A patent/JP5401001B2/ja not_active Expired - Lifetime
- 2003-09-09 EP EP10177178A patent/EP2277532A1/en not_active Withdrawn
- 2003-09-09 DE DE60335552T patent/DE60335552D1/de not_active Expired - Lifetime
- 2003-09-09 EP EP09004342A patent/EP2085096A3/en not_active Ceased
-
2006
- 2006-09-29 US US11/537,270 patent/US20090181024A1/en not_active Abandoned
-
2009
- 2009-12-16 AU AU2009250980A patent/AU2009250980A1/en not_active Withdrawn
-
2010
- 2010-03-15 JP JP2010058499A patent/JP2010187677A/ja active Pending
- 2010-12-14 US US12/967,886 patent/US8431350B2/en not_active Ceased
-
2014
- 2014-03-27 US US14/228,173 patent/USRE46816E1/en not_active Expired - Fee Related
- 2014-03-27 US US14/228,172 patent/USRE46805E1/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/699,845 patent/USRE46534E1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| USRE46816E1 (en) | 2018-05-01 |
| WO2004024068A3 (en) | 2005-02-10 |
| US20110104170A1 (en) | 2011-05-05 |
| USRE46534E1 (en) | 2017-09-05 |
| EP1539228A4 (en) | 2006-04-05 |
| EP2277532A1 (en) | 2011-01-26 |
| EP1539228A2 (en) | 2005-06-15 |
| DE60335552D1 (de) | 2011-02-10 |
| ES2357505T3 (es) | 2011-04-27 |
| JP5401001B2 (ja) | 2014-01-29 |
| CA2498008A1 (en) | 2004-03-25 |
| US8431350B2 (en) | 2013-04-30 |
| USRE46805E1 (en) | 2018-04-24 |
| US20040121370A1 (en) | 2004-06-24 |
| JP2010187677A (ja) | 2010-09-02 |
| JP2006508649A (ja) | 2006-03-16 |
| EP2085096A2 (en) | 2009-08-05 |
| AU2003270439B2 (en) | 2009-09-24 |
| AU2003270439A1 (en) | 2004-04-30 |
| CA2498008C (en) | 2014-02-04 |
| AU2009250980A1 (en) | 2010-01-14 |
| WO2004024068A2 (en) | 2004-03-25 |
| EP2085096A3 (en) | 2009-08-12 |
| EP1539228B1 (en) | 2010-12-29 |
| US20090181024A1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
| ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
| ATE516042T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren | |
| ATE522623T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren | |
| DE602006016934D1 (de) | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen | |
| ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| EP1651164A4 (en) | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS | |
| ATE522229T1 (de) | Anti-ngf-antikörper zur behandlung verschiedener erkrankungen | |
| DE602004030535D1 (de) | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung | |
| WO2005016962A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1469810A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS | |
| DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE602004002394D1 (de) | (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN | |
| EP1487480A4 (en) | HYBRID MOLECULES AND METHODS FOR TREATING IMMUNE DISEASES | |
| ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE69634438D1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1539228 Country of ref document: EP |